California is home to a robust pharmaceutical manufacturing sector characterized by innovation and advanced technology. This industry comprises various companies focused on drug development and production, ranging from small biotech startups to large, established corporations. These firms specialize in unique therapeutic areas, including oncology, autoimmune diseases, and infectious diseases. As the healthcare landscape evolves, California’s pharmaceutical manufacturing industry is aiming to improve patient outcomes with new treatments. With significant investment in research and development, the state continues to play a key role in addressing public health challenges through innovative medical solutions.

The companies listed here vary in size from small teams to thousands of employees, often headquartered in San Diego or South San Francisco. They were founded between 1992 and 2018, showcasing a mix of established and newer entrants in the market. Specializations span a range of areas such as cancer therapies, autoimmune treatment, and antibiotic drug development, reflecting their commitment to tackling pressing health concerns. California's pharmaceutical landscape is characterized by both public and private investment, fostering opportunities for growth and innovation.

Continue reading to discover the top pharmaceutical manufacturing companies in California.

Top 20 Pharmaceutical Manufacturing Companies in California

1. Amplyx, now a subsidiary of Pfizer Inc.

• Website: amplyx.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Latest funding: April 2021
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: amplyx-pharmaceuticals-inc

Amplyx, now a subsidiary of Pfizer Inc., is based in San Diego, California, and was founded in 2006. The company specializes in developing innovative therapies aimed at treating serious infections, particularly in the area of antifungal treatments. Amplyx's research focuses on addressing unmet medical needs in patients with compromised immune systems, such as those undergoing chemotherapy or organ transplants. As part of Pfizer, Amplyx benefits from the extensive resources and research capabilities of one of the largest pharmaceutical companies in the world, allowing it to advance its product pipeline and clinical trials effectively. While Amplyx itself has not reported any recent funding, its integration into Pfizer provides a strong platform for growth and development in the pharmaceutical sector.

2. Agensys, Inc.

• Website: astellas.us
• Ownership type: Private
• Headquarters: Santa Monica, California, United States (USA)
• Founded year: 1997
• Headcount: 201-500
• LinkedIn: agensys

Agensys, Inc., based in Santa Monica, California, operates as a subsidiary of Astellas Pharma US, Inc. Founded in 1997, the company is dedicated to the development and marketing of pharmaceutical products that address critical health issues. Its portfolio includes treatments for oncology, cardiology, and immunology, reflecting a strong commitment to enhancing patient outcomes through innovative therapies. Agensys emphasizes collaboration with healthcare providers and patients, ensuring that their products meet real-world needs. The company is part of a larger global network, contributing to Astellas' mission of improving health and well-being across various therapeutic areas.

3. Prometheus Biosciences, Inc.

• Website: prometheusbiosciences.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $10.8B, April 2023
• Founded year: 1995
• Headcount: 51-200
• LinkedIn: prometheusbiosciences

Prometheus Biosciences, Inc. is a biotechnology firm based in San Diego, California, founded in 1995. The company is dedicated to developing and manufacturing innovative therapies aimed at treating autoimmune diseases, with a particular emphasis on inflammatory bowel disease (IBD). Prometheus is known for its work on monoclonal antibodies, which are designed to target specific pathways involved in these conditions. The company has been involved in various research initiatives and clinical trials to advance its product pipeline. Recently, Prometheus secured significant funding, amounting to $108 million, which underscores investor confidence in its potential to deliver impactful therapies. This financial backing supports their ongoing research and development efforts, positioning them as a notable player in the pharmaceutical manufacturing space.

4. Ajinomoto Bio-Pharma Services

• Website: ajibio-pharma.com
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 49%, Belgium 32%, India 19%
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: ajibio-pharma-services

Ajinomoto Bio-Pharma Services, founded in 1998 and based in San Diego, California, is a private pharmaceutical manufacturer that specializes in contract development and manufacturing organization (CDMO) services. The company offers a comprehensive suite of services, including small and large molecule manufacturing, drug product manufacturing, and development services tailored for biotechnology and pharmaceutical companies. With a workforce of approximately 787 employees, Ajinomoto Bio-Pharma emphasizes quality and compliance in its operations, ensuring that clients can efficiently bring therapeutic products to market. Their facilities are equipped to handle complex manufacturing challenges, and they have a strong track record in supporting clients through various stages of drug development. The company operates globally, with significant employee distribution in Belgium and India, which allows them to cater to a broad client base. Their commitment to innovation and customer satisfaction is evident in their approach to process development and optimization, making them a notable player in the pharmaceutical manufacturing sector.

5. VelosBio Inc.

• Website: velosbio.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Latest funding: $2.8B, November 2020
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: velosbioinc

VelosBio Inc. is a biotechnology firm headquartered in San Diego, California, that specializes in the development of targeted therapies for cancer. Founded in 2017, the company has quickly positioned itself within the pharmaceutical industry by focusing on innovative solutions to combat various forms of cancer. VelosBio's research is centered around the development of monoclonal antibodies and other therapeutic modalities aimed at improving patient outcomes. The company gained significant attention in November 2020 when it secured $275 million in funding, which underscores its potential and the confidence investors have in its pipeline of products. VelosBio is committed to advancing cancer treatment through rigorous research and clinical trials, making it a notable entity in the pharmaceutical manufacturing sector.

6. Portola Pharmaceuticals

• Website: portola.com
• Ownership type: Corporate
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 93%, United Kingdom (UK) 7%
• Latest funding: $1.4B, May 2020
• Founded year: 2003
• Headcount: 201-500
• LinkedIn: portola-pharmaceuticals

Portola Pharmaceuticals, founded in 2003 and based in South San Francisco, California, is a biopharmaceutical company that specializes in creating therapies for patients suffering from rare and serious diseases. The company is known for its innovative products, including KANUMA, SOLIRIS, STRENSIQ, and ULTOMIRIS, which cater to specific health needs within the rare disease community. Portola's focus on research and development is evident in its commitment to delivering effective treatment options and support for patients and healthcare providers. The company has received significant funding, amounting to $1.4 billion, which underscores its potential for growth and impact in the pharmaceutical sector. As part of Alexion Pharmaceuticals, Portola continues to play a crucial role in advancing medical solutions for underserved patient populations.

7. Vivera Pharmaceuticals

• Website: viverapharmaceuticals.com
• Ownership type: Private
• Headquarters: Newport Beach, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $440.0M, November 2020
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: viverapharmaceuticals

Vivera Pharmaceuticals, Inc. is a biopharma and medtech company based in Newport Beach, California, founded in 2018. The company specializes in creating innovative therapies and medical devices aimed at improving health outcomes, particularly in pain management. Vivera holds global exclusivity for the patented TABMELT sublingual drug delivery system, which is designed for pharmaceutical use. They also developed the ZICOH electronic dispensing device, showcasing their focus on advanced drug delivery technologies. With a commitment to research and development, Vivera is actively working on non-addictive treatment alternatives and has established multiple divisions, including technologies, biosciences, medical devices, and advanced diagnostics. The company has secured significant funding, amounting to $440 million as of November 2020, which supports its ongoing projects and innovations. Vivera's mission extends beyond product development; through its non-profit organization, Vivera Cares, the company aims to assist underserved communities, further solidifying its role in the healthcare sector.

8. Myovant Sciences

• Website: myovant.com
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 95%, Other 5%
• Latest funding: $1.7B, October 2022
• Founded year: 2016
• Headcount: 501-1000
• LinkedIn: myovant-sciences

Myovant Sciences, founded in 2016 and based in Brisbane, California, is a pharmaceutical company dedicated to developing innovative treatments primarily in women's health and oncology. The company operates under the umbrella of Sumitomo Pharma America, Inc., which allows it to leverage extensive resources and expertise in drug discovery and development. Myovant's pipeline includes products aimed at addressing significant health challenges, particularly in areas where patient needs are high or unmet. The company has received substantial funding, totaling $1.7 billion as of October 2022, which underscores its potential for growth and innovation in the pharmaceutical sector. Myovant's focus on patient-first solutions and advanced technology in drug development further solidifies its role in the pharmaceutical manufacturing industry.

9. Nivagen Pharmaceuticals, Inc.

• Website: nivagen.com
• Ownership type: Venture Capital
• Headquarters: Sacramento, California, United States (USA)
• Employee distribution: United States (USA) 51%, India 49%
• Latest funding: $5.0M, August 2023
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: nivagen-pharmaceuticals

Nivagen Pharmaceuticals, Inc. is a pharmaceutical company based in Sacramento, California, founded in 2009. The company specializes in the development, manufacturing, and marketing of generic and specialty drugs, with a particular emphasis on sterile injectables such as IV bags, vials, pre-filled syringes, and cartridges. Nivagen serves healthcare providers and institutions by offering affordable, high-quality products while addressing market shortages through advanced manufacturing capabilities and research and development services. The company operates a state-of-the-art sterile manufacturing facility in Sacramento, which spans 100,000 square feet and is designed to produce various dosage forms. Nivagen is also involved in contract development and manufacturing organization (CDMO) services, providing end-to-end solutions from drug development to commercialization. Their recent funding of over $5 million in August 2023 further supports their growth and innovation initiatives in the pharmaceutical sector.

10. sanofi us

• Website: sanofi.us
• Ownership type: Private
• Headquarters: Irvine, California, United States (USA)
• Employee distribution: United States (USA) 87%, Brazil 3%, China 3%, Other 6%
• Founded year: 2004
• Headcount: 10001+
• LinkedIn: sanofi-us

Sanofi US, based in Irvine, California, is a prominent pharmaceutical company that specializes in creating and providing innovative healthcare solutions. Founded in 2004, the company has grown to employ over 10,000 individuals in the U.S. alone. Sanofi US focuses on a broad spectrum of health needs, offering prescription medications, vaccines, and consumer health products. Their product lines address various medical conditions, including immunology, neurology, oncology, and rare diseases. Sanofi US is also involved in significant clinical trials, showcasing their commitment to research and development. The company operates with a strong emphasis on social impact, patient advocacy, and corporate responsibility, aiming to improve health outcomes for communities and individuals alike.

11. Aimmune Therapeutics

• Website: aimmune.com
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 81%, United Kingdom (UK) 10%, Switzerland 5%, Other 4%
• Latest funding: $2.6B, August 2020
• Founded year: 2011
• Headcount: 501-1000
• LinkedIn: aimmune-therapeutics

Aimmune Therapeutics, based in Brisbane, California, is a biopharmaceutical company founded in 2011. The company is dedicated to developing innovative therapies aimed at treating food allergies and related gastrointestinal and metabolic diseases. Aimmune's mission is to transform the lives of patients and their families by providing effective treatments that improve quality of life. They collaborate with prominent biotechnology firms to advance their research and development efforts. Aimmune has garnered significant financial backing, with a reported funding amount of $2.6 billion as of August 2020, which underscores the confidence investors have in their potential to deliver groundbreaking therapies. Their focus on regulatory-approved, science-driven treatments positions them as a key player in the pharmaceutical industry, particularly in the allergy treatment sector.

12. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, founded in 1992 and based in Seal Beach, California, is a biotechnology company that focuses on immunotherapy for cancer treatment. The company is best known for its flagship product, Provenge (sipuleucel-T), which is the first FDA-approved immunotherapy that utilizes a patient's own immune cells to combat advanced prostate cancer. Since its approval in 2010, Provenge has been prescribed to nearly 40,000 men, demonstrating its impact on patient outcomes. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, supporting the development and commercialization of innovative cancer therapies. The company has a robust infrastructure for clinical and commercial manufacturing, with facilities designed to ensure high-quality production of cellular therapies. Dendreon's commitment to advancing cancer treatment through research, development, and strategic partnerships highlights its significant role in the pharmaceutical manufacturing industry.

13. HUYABIO International

• Website: huyabio.com
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 72%, China 15%, Japan 6%, Other 8%
• Latest funding: Other (Debt), $48.0M, April 2015
• Founded year: 2004
• Headcount: 51-200
• LinkedIn: huya-bioscience-international

HUYABIO International, founded in 2004 and based in San Diego, California, is a biopharmaceutical company dedicated to globalizing pharmaceutical innovations from China. The company specializes in developing novel therapeutic compounds, particularly in the fields of oncology and cardiovascular health. HUYABIO collaborates with various research institutions and pharmaceutical companies to identify and license promising pre-clinical and clinical stage compounds. Their pipeline includes several noteworthy programs, such as HBI-8000, an innovative oncology drug, and HBI-3000, aimed at treating atrial fibrillation. HUYABIO's strategic partnerships and extensive compound portfolio reflect their commitment to addressing significant medical needs. The company has also secured funding, with a notable amount of $48 million in 2015, which supports their ongoing research and development efforts.

14. Qpex Biopharma

• Website: qpexbio.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $10.0M, May 2024
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: qpex-biopharma-inc

Qpex Biopharma, based in San Diego, California, is a biopharmaceutical company established in 2018. The company is dedicated to developing innovative antibiotics aimed at combating antimicrobial resistance, a significant global health challenge. Their product pipeline includes OMNIvance®, ORAvance™, and QPX9003, which target drug-resistant infections. Qpex collaborates with healthcare organizations to enhance patient care through effective treatments for serious infections. The company has a strong focus on research and development, often partnering with public and private entities to advance their clinical programs. Recently, Qpex received a $10 million grant to support their initiatives, highlighting their commitment to addressing urgent medical needs. In 2023, Qpex became a wholly-owned subsidiary of Shionogi Inc., further expanding its capabilities in the infectious disease sector.

15. Antheia, Inc.

• Website: antheia.bio
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $12.0M, December 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: antheiabio

Antheia, Inc., founded in 2015 and based in Menlo Park, California, is a biotechnology company that specializes in pharmaceutical manufacturing through synthetic biology. The company focuses on producing biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) to tackle drug shortages and enhance supply chain efficiency for pharmaceutical companies and healthcare providers. Antheia's innovative platform allows for the rapid and sustainable production of essential medicines, utilizing contained fermentation environments to ensure reliable and consistent yields. The company has garnered attention for its potential to transform traditional pharmaceutical manufacturing processes, making them more agile and environmentally friendly. Recently, Antheia secured $12 million in funding, which underscores its commitment to advancing its biomanufacturing capabilities and addressing critical healthcare needs.

16. ShouTi

• Website: shoutipharma.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Latest funding: $100.0M, October 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: shouti

ShouTi is a biopharmaceutical company based in South San Francisco, California, founded in 2017. The company specializes in drug development and research, with a particular focus on creating innovative oral therapies for chronic diseases. ShouTi aims to address unmet clinical needs in healthcare by leveraging advanced computational chemistry and structure-based drug discovery techniques. Their drug development platform integrates cutting-edge technologies to design and develop small molecule drugs that can overcome the limitations of current biotherapeutics and peptide therapies. ShouTi has received substantial funding, with a reported $100 million raised in October 2021, which supports their ongoing research and development efforts. The company is committed to improving patient outcomes and enhancing healthcare through the development of effective medications.

17. pH Pharma Inc.

• Website: ph-pharma.com
• Ownership type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Latest funding: January 2018
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: ph-pharma-co.-ltd.

pH Pharma Inc., founded in 2015 and based in Palo Alto, California, is a biotechnology firm dedicated to developing innovative healthcare products aimed at addressing unmet clinical needs. The company specializes in drug development for conditions such as glaucoma and non-alcoholic steatohepatitis (NASH). With a focus on both research and manufacturing, pH Pharma collaborates with a global network to enhance its research capabilities. Their pipeline includes promising candidates like Sovesudil, which is currently undergoing clinical trials for glaucoma treatment. The company has also engaged in partnerships for the development of antibody-drug conjugates (ADCs), showcasing its commitment to advancing cancer therapies. pH Pharma's strategic approach and ongoing clinical efforts reflect its active role in the pharmaceutical industry.

18. Pharmatek

• Website: pharmatek.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2016
• Founded year: 1999
• Headcount: 201-500
• LinkedIn: pharmatek-laboratories-inc-

Pharmatek, known as Catalent, is a contract development and manufacturing organization based in San Diego, California. Founded in 1999, the company has grown to employ between 201 and 500 individuals, all based in the United States. Catalent specializes in providing pharmaceutical and biotechnology services, focusing on drug development, manufacturing, and delivery. Their offerings include a wide range of solutions tailored to meet the needs of pharmaceutical and biotech companies, helping them optimize their product development processes. Catalent's expertise spans various areas, including oral dose formulation, biologics, and clinical supply services. They are dedicated to assisting clients in navigating the complexities of bringing new therapies to market, ensuring that their products are developed efficiently and effectively.

19. Respira Therapeutics, Inc.

• Website: respiratherapeutics.com
• Ownership type: Corporate
• Headquarters: Palo Alto, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, November 2015
• Founded year: 2010
• Headcount: 1-10
• LinkedIn: respira-therapeutics-inc-

Respira Therapeutics, Inc., based in Palo Alto, California, is a biotechnology firm established in 2010. The company specializes in the development of inhalation therapies aimed at treating respiratory diseases, with a particular focus on pulmonary arterial hypertension (PAH). Their flagship product, RT234, is a first-in-class inhaled therapy designed for as-needed use, which contrasts with existing PAH treatments that require continuous administration. Respira employs advanced particle engineering and proprietary device technologies to enhance drug delivery to the lungs. The company is currently conducting Phase 2 clinical trials to validate the efficacy and safety of RT234, demonstrating their active involvement in the pharmaceutical industry. With a small team of around 17 employees, Respira is dedicated to addressing significant unmet needs in respiratory care through innovative therapeutic solutions.

20. IriSys, LLC, is now Societal CDMO

• Website: irisys.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $50.0M, August 2021
• Founded year: 1996
• Headcount: 51-200
• LinkedIn: irisysllc

Societal CDMO, previously IriSys, LLC, is a pharmaceutical contract development and manufacturing organization based in San Diego, California. Founded in 1996, the company specializes in clinical and commercial cGMP manufacturing, formulation development, and clinical trial services. They assist pharmaceutical and biotechnology clients in navigating the complexities of drug development and ensuring compliance with regulatory standards. Societal CDMO offers a range of capabilities, including manufacturing for injectables, oral liquids, and oral solids, as well as quality assurance and regulatory support. The company has received significant funding, with a reported amount of $50 million in August 2021, which underscores their active role in the industry and commitment to enhancing their service offerings.

Pharmaceutical Manufacturing Insights: Key Companies in California

Want to Find More Pharmaceutical Manufacturing Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!